Search

Author/Creator Mittendorf, Elizabeth A

8. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. (February 2011)

Authors:
Benavides, Linda C; Sears, Alan K; Gates, Jeremy D; Clifton, Guy T; Clive, Kevin S; Carmichael, Mark G; Holmes, Jarrod P; Mittendorf, Elizabeth A; Ponniah, Sathibalan; Peoples, George E
Journal:
Expert review of vaccines
Issue:
Volume 10:Number 2(2011)
Page Start:
201
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine. (4th November 2015)

Authors:
Anastasopoulou, Eleftheria A; Tzonis, Panagiotis; Fortis, Sotirios P; Mahaira, Louisa; Vaxevanis, Christoforos; Ardavanis, Alexandros; Mittendorf, Elizabeth A; Peoples, George E; Baxevanis, Constantin N; Papamichail, Michael; Perez, Sonia A
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Expanding Criteria for Prognostic Stage IA in Hormone Receptor–Positive Breast Cancer. (19th May 2021)

Authors:
Kantor, Olga; King, Tari A; Shak, Steven; Russell, Christy A; Giuliano, Armando E; Hortobagyi, Gabriel N; Burstein, Harold J; Winer, Eric P; Dey, Tanujit; Sparano, Joseph A; Mittendorf, Elizabeth A
Journal:
Journal of the National Cancer Institute
Issue:
Volume 113:Number 12(2021)
Page Start:
1744
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗